SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

NCT04684108 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma
Hematological Malignancy

Interventions

DRUG: SG301

Sponsor

Hangzhou Sumgen Biotech Co., Ltd.